Oligodendrocytes in neurodegenerative diseases

Abstract

Oligodendrocyte is a highly specialized glial cell type in the vertebrate central nervous system, which guarantees the long-distance transmission of action potential by producing myelin sheath wrapping adjacent axons. Disrupted myelin and oligodendrocytes are hallmarks of some devastating neurological diseases, such as multiple sclerosis, although their contribution to neurodegeneration in a given disease is still controversial. However, accumulating evidence from clinical studies and genetic animal models implicates oligodendrocyte dysfunction as one of major events in the processes of initiation and progression of neurodegeneration. In this article, we will review recent progress in understanding non-traditional function of oligodendrocytes in neuronal support and protection independent of myelin sheath and its possible contribution to neurodegeneration. Oligodendrocytes play a pivotal role in neurodegenerative diseases among which special emphasis is given to multiple system atrophy and Alzheimer’s disease in this review.

Keywords

Glia / oligodendrocyte / neurodegenerative disease / myelin sheath / multiple sclerosis / multiple system atrophy / Alzheimer’s disease / Parkinson’s disease

References

[1] Anderson T J, Schneider A, Barrie J A, Klugmann M, McCulloch M C, Kirkham D, Kyriakides E, Nave K A, Griffiths I R (1998). Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol, 394(4): 506-519

[2] Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (1998). NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol, 96(5): 439-444

[3] Bartzokis G (2004). Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease. Neurobiol Aging, 25(1): 5-18, author reply 49-62

[4] Benrud-Larson L M, Sandroni P, Schrag A, Low P A (2005). Depressive symptoms and life satisfaction in patients with multiple system atrophy. Mov Disord, 20(8): 951-957

[5] Breteler M M, Claus J J, van Duijn C M, Launer L J, Hofman A (1992). Epidemiology of Alzheimer’s disease. Epidemiol Rev, 14: 59-82

[6] Buch T, Heppner F L, Tertilt C, Heinen T J, Kremer M, Wunderlich F T, Jung S, Waisman A (2005). A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods, 2(6): 419-426

[7] Desai M K, Guercio B J, Narrow W C, Bowers W J (2011). An Alzheimer’s disease-relevant presenilin-1 mutation augments amyloid-beta-induced oligodendrocyte dysfunction. Glia, 59(4): 627-640

[8] Desai M K, Mastrangelo M A, Ryan D A, Sudol K L, Narrow W C, Bowers W J (2010). Early oligodendrocyte/myelin pathology in Alzheimer’s disease mice constitutes a novel therapeutic target. Am J Pathol, 177(3): 1422-1435

[9] Desai M K, Sudol K L, Janelsins M C, Mastrangelo M A, Frazer M E, Bowers W J (2009). Triple-transgenic Alzheimer’s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia, 57(1): 54-65

[10] Dickson D W, Lin W, Liu W K, Yen S H (1999). Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol, 9(4): 721-732

[11] Edgar J M, McLaughlin M, Barrie J A, McCulloch M C, Garbern J, Griffiths I R (2004). Age-related axonal and myelin changes in the rumpshaker mutation of the Plp gene. Acta Neuropathol, 107(4): 331-335

[12] Feigenbaum V, Gélot A, Casanova P, Daumas-Duport C, Aubourg P, Dubois-Dalcq M (2000). Apoptosis in the central nervous system of cerebral adrenoleukodystrophy patients. Neurobiol Dis, 7(6 6 Pt B): 600-612

[13] Fellner L, Jellinger K A, Wenning G K, Stefanova N (2011). Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol, 121(6): 675-693

[14] Fünfschilling U, Supplie L M, Mahad D, Boretius S, Saab A S, Edgar J, Brinkmann B G, Kassmann C M, Tzvetanova I D, Möbius W, Diaz F, Meijer D, Suter U, Hamprecht B, Sereda M W, Moraes C T, Frahm J, Goebbels S, Nave K A (2012). Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature, 485(7399): 517-521

[15] Garcia-Ladona F J, Huss Y, Frey P, Ghandour M S (1997). Oligodendrocytes express different isoforms of beta-amyloid precursor protein in chemically defined cell culture conditions: in situ hybridization and immunocytochemical detection. J Neurosci Res, 50(1): 50-61

[16] Ghosh A, Manrique-Hoyos N, Voigt A, Schulz J B, Kreutzfeldt M, Merkler D, Simons M (2011). Targeted ablation of oligodendrocytes triggers axonal damage. PLoS ONE, 6(7): e22735

[17] Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab M H, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave K A (1998). Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science, 280(5369): 1610-1613

[18] Harrington E P, Zhao C, Fancy S P, Kaing S, Franklin R J, Rowitch D H (2010). Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination. Ann Neurol, 68(5): 703-716

[19] Heneka M T, Rodríguez J J, Verkhratsky A (2010). Neuroglia in neurodegeneration. Brain Res Brain Res Rev, 63(1-2): 189-211

[20] Higuchi M, Zhang B, Forman M S, Yoshiyama Y, Trojanowski J Q, Lee V M (2005). Axonal degeneration induced by targeted expression of mutant human tau in oligodendrocytes of transgenic mice that model glial tauopathies. J Neurosci, 25(41): 9434-9443

[21] Jantaratnotai N, Ryu J K, Kim S U, McLarnon J G (2003). Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport, 14(11): 1429-1433

[22] Kahle P J (2008). alpha-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol, 115(1): 87-95

[23] Kahle P J, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, Fuss B, Mallon B, Macklin W B, Fujiwara H, Hasegawa M, Iwatsubo T, Kretzschmar H A, Haass C (2002). Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep, 3(6): 583-588

[24] Kassmann C M, Lappe-Siefke C, Baes M, Brügger B, Mildner A, Werner H B, Natt O, Michaelis T, Prinz M, Frahm J, Nave K A (2007). Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet, 39(8): 969-976

[25] Kato S, Nakamura H (1990). Cytoplasmic argyrophilic inclusions in neurons of pontine nuclei in patients with olivopontocerebellar atrophy: immunohistochemical and ultrastructural studies. Acta Neuropathol, 79(6): 584-594

[26] Kato S, Nakamura H, Hirano A, Ito H, Llena J F, Yen S H (1991). Argyrophilic ubiquitinated cytoplasmic inclusions of Leu-7-positive glial cells in olivopontocerebellar atrophy (multiple system atrophy). Acta Neuropathol, 82(6): 488-493

[27] Kohama S G, Rosene D L, Sherman L S (2011). Age-related changes in human and non-human primate white matter: from myelination disturbances to cognitive decline. Age, 34(5): 1093-1110

[28] Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, Griffiths IR, Nave KA(2003). Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet, 33(3): 366-374

[29] Lasiene J, Matsui A, Sawa Y, Wong F, Horner P J (2009). Age-related myelin dynamics revealed by increased oligodendrogenesis and short internodes. Aging Cell, 8(2): 201-213

[30] Lee J T, Xu J, Lee J M, Ku G, Han X, Yang D I, Chen S, Hsu C Y (2004). Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J Cell Biol, 164(1): 123-131

[31] Lee Y, Morrison B M, Li Y, Lengacher S, Farah M H, Hoffman P N, Liu Y, Tsingalia A, Jin L, Zhang P W, Pellerin L, Magistretti P J, Rothstein J D (2012). Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature, 487(7408): 443-448

[32] Locatelli G, Wörtge S, Buch T, Ingold B, Frommer F, Sobottka B, Krüger M, Karram K, Bühlmann C, Bechmann I, Heppner F L, Waisman A, Becher B (2012). Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci, 15(4): 543-550

[33] Mena M A, García de Yébenes J (2008). Glial cells as players in parkinsonism: the “good,” the “bad,” and the “mysterious” glia. Neuroscientist, 14(6): 544-560

[34] Mitew S, Kirkcaldie M T, Halliday G M, Shepherd C E, Vickers J C, Dickson T C (2010). Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol, 119(5): 567-577

[35] Nave K A (2010a). Myelination and support of axonal integrity by glia. Nature, 468(7321): 244-252

[36] Nave K A (2010b). Myelination and the trophic support of long axons. Nat Rev Neurosci, 11(4): 275-283

[37] Nave K A, Trapp B D (2008). Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci, 31(1): 535-561

[38] Oluich L J, Stratton J A, Xing Y L, Ng S W, Cate H S, Sah P, Windels F, Kilpatrick T J, Merson T D (2012). Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination. J Neurosci, 32(24): 8317-8330

[39] Ozawa T, Paviour D, Quinn N P, Josephs K A, Sangha H, Kilford L, Healy D G, Wood N W, Lees A J, Holton J L, Revesz T (2004). The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain, 127(Pt 12): 2657-2671

[40] Papp M I, Kahn J E, Lantos P L (1989). Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci, 94(1-3): 79-100

[41] Papp M I, Lantos P L (1992). Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci, 107(2): 172-182

[42] Pfeiffer R F (2007). Multiple system atrophy. Handb Clin Neurol, 84: 305-326

[43] Pohl H B, Porcheri C, Mueggler T, Bachmann L C, Martino G, Riethmacher D, Franklin R J, Rudin M, Suter U (2011). Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci, 31(3): 1069-1080

[44] Roher A E, Weiss N, Kokjohn T A, Kuo Y M, Kalback W, Anthony J, Watson D, Luehrs D C, Sue L, Walker D, Emmerling M, Goux W, Beach T (2002). Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry, 41(37): 11080-11090

[45] Rowe W B, Blalock E M, Chen K C, Kadish I, Wang D, Barrett J E, Thibault O, Porter N M, Rose G M, Landfield P W (2007). Hippocampal expression analyses reveal selective association of immediate-early, neuroenergetic, and myelinogenic pathways with cognitive impairment in aged rats. J Neurosci, 27(12): 3098-3110

[46] Schiffmann R, van der Knaap M S (2004). The latest on leukodystrophies. Curr Opin Neurol, 17(2): 187-192

[47] Shin D, Shin J Y, McManus M T, Ptácek L J, Fu Y H (2009). Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann Neurol, 66(6): 843-857

[48] Shults C W, Rockenstein E, Crews L, Adame A, Mante M, Larrea G, Hashimoto M, Song D, Iwatsubo T, Tsuboi K, Masliah E (2005). Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci, 25(46): 10689-10699

[49] Singh S, Swarnkar S, Goswami P, Nath C (2011). Astrocytes and microglia: responses to neuropathological conditions. Int J Neurosci, 121(11): 589-597

[50] Sloane J A, Hinman J D, Lubonia M, Hollander W, Abraham C R (2003). Age-dependent myelin degeneration and proteolysis of oligodendrocyte proteins is associated with the activation of calpain-1 in the rhesus monkey. J Neurochem, 84(1): 157-168

[51] Soma H, Yabe I, Takei A, Fujiki N, Yanagihara T, Sasaki H (2006). Heredity in multiple system atrophy. J Neurol Sci, 240(1-2): 107-110

[52] Spillantini M G, Crowther R A, Jakes R, Cairns N J, Lantos P L, Goedert M (1998). Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett, 251(3): 205-208

[53] Stefanova N, Bücke P, Duerr S, Wenning G K (2009). Multiple system atrophy: an update. Lancet Neurol, 8(12): 1172-1178

[54] Stefanova N, Reindl M, Neumann M, Kahle P J, Poewe W, Wenning G K (2007). Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord, 22(15): 2196-2203

[55] Stemberger S, Poewe W, Wenning G K, Stefanova N (2010). Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure. Exp Neurol, 224(2): 459-464

[56] Tanaka J, Okuma Y, Tomobe K, Nomura Y (2005). The age-related degeneration of oligodendrocytes in the hippocampus of the senescence-accelerated mouse (SAM) P8: a quantitative immunohistochemical study. Biol Pharm Bull, 28(4): 615-618

[57] Trapp B D, Nave K A (2008). Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci, 31(1): 247-269

[58] Tu P H, Galvin J E, Baba M, Giasson B, Tomita T, Leight S, Nakajo S, Iwatsubo T, Trojanowski J Q, Lee V M (1998). Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol, 44(3): 415-422

[59] Ubhi K, Low P, Masliah E (2011). Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci, 34(11): 581-590

[60] Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E (2010). Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci, 30(18): 6236-6246

[61] Valenza M, Cattaneo E (2011). Emerging roles for cholesterol in Huntington’s disease. Trends Neurosci, 34(9): 474-486

[62] Valenza M, Leoni V, Karasinska J M, Petricca L, Fan J, Carroll J, Pouladi M A, Fossale E, Nguyen H P, Riess O, MacDonald M, Wellington C, DiDonato S, Hayden M, Cattaneo E (2010). Cholesterol defect is marked across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J Neurosci, 30(32): 10844-10850

[63] Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H (1998). Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett, 249(2-3): 180-182

[64] Wenning G K, Stefanova N, Jellinger K A, Poewe W, Schlossmacher M G (2008). Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol, 64(3): 239-246

[65] Yazawa I, Giasson B I, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski J Q, Lee V M (2005). Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron, 45(6): 847-859

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg